Alpine Immune Sciences News Releases http://ir.alpineimmunesciences.com/ Alpine Immune Sciences News Releases en Alpine Immune Sciences Appoints Biopharma Veteran Wayne Gombotz as Chief Technology Officer http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-appoints-biopharma-veteran-wayne-gombotz SEATTLE --(BUSINESS WIRE)--Jun. 3, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the appointment of Wayne Gombotz , PhD as Chief Mon, 03 Jun 2019 07:35:00 -0400 Alpine Immune Sciences News Releases 8116 Alpine Immune Sciences to Present at Upcoming Investor Conferences http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-present-upcoming-investor-conferences SEATTLE --(BUSINESS WIRE)--May 24, 2019-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in three upcoming Fri, 24 May 2019 07:35:00 -0400 Alpine Immune Sciences News Releases 8101 Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products http://ir.alpineimmunesciences.com/news-releases/news-release-details/adaptimmune-and-alpine-immune-sciences-announce-collaboration PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ: ALPN ), a leading immunotherapy company focused on developing treatments Wed, 15 May 2019 08:00:00 -0400 Alpine Immune Sciences News Releases 8081 Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial Results http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-provides-corporate-update-and-reports-4 Alpine transitions to clinical-stage company Completed financing to fund further development of both lead programs SEATTLE --(BUSINESS WIRE)--May 9, 2019-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for Thu, 09 May 2019 07:25:00 -0400 Alpine Immune Sciences News Releases 8061 Alpine Immune Sciences Appoints Stanford Peng to President and Head of Research and Development http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-appoints-stanford-peng-president-and-head SEATTLE --(BUSINESS WIRE)--Apr. 18, 2019-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN) (“Alpine”), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced Stanford Peng , M.D. Thu, 18 Apr 2019 08:00:00 -0400 Alpine Immune Sciences News Releases 8041 Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-provides-corporate-update-and-reports-3 First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 Completed $25 Million Private Placement Strong Financial Position to Transition Two Lead Programs ALPN-101 and ALPN-202 into Patients SEATTLE --(BUSINESS WIRE)--Mar. Mon, 18 Mar 2019 07:30:00 -0400 Alpine Immune Sciences News Releases 7971 Alpine Immune Sciences to Present at Two Upcoming Investor Conferences http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-present-two-upcoming-investor-1 SEATTLE --(BUSINESS WIRE)--Feb. 27, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming Wed, 27 Feb 2019 07:00:00 -0500 Alpine Immune Sciences News Releases 7956 Alpine Immune Sciences Presents Preclinical ALPN-101 GvHD Data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings) http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-presents-preclinical-alpn-101-gvhd-data Appoints Immunology Veteran Vijay Kuchroo, DVM, PhD to Scientific Advisory Board SEATTLE --(BUSINESS WIRE)--Feb. 19, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and Tue, 19 Feb 2019 07:00:00 -0500 Alpine Immune Sciences News Releases 7941 Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101 http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-announces-first-subjects-dosed-phase-i First Dual ICOS/CD28 Inhibitor to Enter Clinical Trials SEATTLE --(BUSINESS WIRE)--Feb. 11, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today Mon, 11 Feb 2019 07:00:00 -0500 Alpine Immune Sciences News Releases 7931 Alpine Immune Sciences Announces $25 Million Private Placement http://ir.alpineimmunesciences.com/news-releases/news-release-details/alpine-immune-sciences-announces-25-million-private-placement SEATTLE --(BUSINESS WIRE)--Jan. 16, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company dedicated to developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities Wed, 16 Jan 2019 07:00:00 -0500 Alpine Immune Sciences News Releases 7801